放射線毒性治療の世界市場- 産業規模、シェア、動向、機会、予測、2018年～2028年：製品別、適応症別、放射線タイプ別、エンドユーザー別、地域別、競合分析

世界の放射線毒性治療市場は、2022年に22億3,000万米ドルと評価され、2028年までのCAGRは5.43%で、予測期間中に力強い成長を予測しています。

放射線毒性治療の世界市場は、がんの発生率の増加やがん治療における放射線治療の利用拡大が原動力となり、近年著しい成長と進化を遂げています。放射線療法は腫瘍学において極めて重要な手段であるが、放射線毒性を引き起こす可能性があり、しばしば専門的な治療や管理戦略が必要となります。この市場には、放射線療法の副作用を緩和・治療することを目的とした幅広い製品とサービスが含まれており、放射線療法は現代のがん治療にとって不可欠な要素となっています。

この市場の成長促進要因のひとつは、世界のがん罹患率の上昇です。がんの罹患率が世界的に上昇を続ける中、放射線療法を受ける患者数は大幅に増加しています。しかし、放射線療法に副作用がないわけではなく、皮膚反応、胃腸障害、臓器障害などの放射線毒性が一般的な懸念事項となっています。このため、医薬品、医療機器、支持療法サービスなど、放射線毒性治療オプションの需要に拍車がかかっています。医薬品は放射線毒性治療市場の重要なセグメントを形成しており、放射線毒性の症状を管理・緩和するために開発された医薬品や薬剤があります。これらの医薬品には、抗炎症剤、成長因子、放射線防護薬などが含まれます。さらに、標的治療薬や免疫調節薬の進歩は、放射線治療の効果を向上させると同時に、関連する毒性を軽減させることが期待されています。

高度な放射線照射システムや画像技術などの医療機器も、この市場の成長に大きく貢献しています。これらの技術革新は放射線治療の精度を高め、健康な組織の放射線被曝を最小限に抑え、それによって毒性を軽減します。さらに、陽子線治療やブラキセラピー技術の採用が増加していることも、高度な放射線毒性治療ソリューションの需要をさらに押し上げています。栄養カウンセリング、理学療法、心理社会的サポートを含む支持療法サービスおよび療法は、放射線毒性管理に不可欠な要素であり、市場はこれらのニーズに応えるさまざまなソリューションを提供しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の放射線毒性治療市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別（コロニー刺激因子、ヨウ化カリウム、プルシアンブルー・ジエチレントリアミン五酢酸、その他）
  • 適応症別（急性放射線症候群、慢性放射線症候群）
  • 放射線タイプ別（電離放射線、非電離放射線）
  • エンドユーザー別（病院・クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 製品別
  • 適応症別
  • 放射線タイプ別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋の放射線毒性治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 放射線タイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の放射線毒性治療市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 放射線タイプ別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の放射線毒性治療市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • エンドユーザー別
  • 放射線タイプ別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の放射線毒性治療市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの放射線毒性治療市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 薬剤タイプ別
  • 放射線タイプ別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の放射線毒性治療市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Amgen Inc.
• Jubilant Pharma Limited
• Tanner Pharma Group
• Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
• Recipharm AB
• Mission Pharmacal Company
• Partner Therapeutics, Inc.
• Novartis AG
• Mylan NV
• Coherus Biosciences Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Radiation Toxicity Treatment Market has valued at USD 2.23 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.43% through 2028. The Global Radiation Toxicity Treatment Market has witnessed significant growth and evolution in recent years, driven by the increasing incidence of cancer and the expanding use of radiation therapy in cancer treatment. Radiation therapy, while a crucial tool in oncology, can lead to radiation toxicity, which often necessitates specialized treatments and management strategies. This market encompasses a wide range of products and services aimed at mitigating and treating the adverse effects of radiation therapy, making it an essential component of modern cancer care.

One of the primary drivers of this market's growth is the rising global cancer burden. As cancer incidence continues to rise worldwide, the number of patients undergoing radiation therapy has increased substantially. However, radiation therapy is not without its side effects, and radiation toxicity, including skin reactions, gastrointestinal issues, and organ damage, is a common concern. This has spurred the demand for radiation toxicity treatment options, including pharmaceuticals, medical devices, and supportive care services. Pharmaceuticals form a crucial segment of the radiation toxicity treatment market, with drugs and medications developed to manage and alleviate the symptoms of radiation toxicity. These pharmaceuticals include anti-inflammatory agents, growth factors, and radioprotective drugs. Additionally, advancements in targeted therapies and immunomodulators hold promise for improving the effectiveness of radiation therapy while reducing associated toxicities.

Medical devices, such as advanced radiation delivery systems and imaging technologies, also contribute significantly to this market's growth. These innovations enhance the precision of radiation therapy, minimizing the exposure of healthy tissues to radiation and thereby reducing toxicity. Moreover, the growing adoption of proton therapy and brachytherapy techniques has further driven the demand for advanced radiation toxicity treatment solutions. Supportive care services and therapies, including nutritional counseling, physical therapy, and psychosocial support, are an integral part of radiation toxicity management, and the market offers a range of solutions to cater to these needs..

Key Market Drivers

Increasing Cancer Prevalence

The Global Radiation Toxicity Treatment Market is experiencing a significant boost due to the alarming rise in cancer prevalence worldwide. Cancer has evolved into a global health crisis, with its incidence steadily increasing year by year. According to the World Health Organization (WHO), cancer is a leading cause of mortality, and the number of new cases is projected to surge in the coming decades. This escalating cancer burden has directly contributed to the expansion of the radiation toxicity treatment market.

As cancer continues to affect millions of individuals across the globe, radiation therapy has emerged as a critical modality for its treatment. Radiation therapy is employed in various stages of cancer management, including curative intent, adjuvant therapy, and palliative care. However, it is not without its drawbacks, as it can lead to radiation-induced toxicities in healthy tissues surrounding the tumor site. These toxicities can significantly impact a patient's quality of life and, in some cases, necessitate treatment interruptions.

Consequently, the growing reliance on radiation therapy has led to a corresponding surge in demand for radiation toxicity treatment options. Patients and healthcare providers alike are seeking innovative solutions to mitigate the adverse effects of radiation therapy and enhance treatment tolerability. This has prompted substantial investments in research and development within the radiation toxicity treatment sector.

Pharmaceuticals, radioprotective agents, medical devices, and supportive care services have all emerged as integral components of the radiation toxicity treatment market. These offerings aim to alleviate radiation-induced side effects, enhance treatment outcomes, and ultimately improve the patient experience. Additionally, advancements in targeted therapies and personalized medicine are opening new avenues for tailoring radiation therapy to individual patients, further driving market growth.

Expanding Utilization of Radiation Therapy

The Global Radiation Toxicity Treatment Market is experiencing a significant boost due to the expanding utilization of radiation therapy in the field of oncology. Radiation therapy, also known as radiotherapy, plays a pivotal role in the treatment of cancer, and its increasing adoption is a key driver behind the market's growth.

Radiation therapy is employed at various stages of cancer treatment, including as a primary curative treatment, adjuvant therapy to prevent cancer recurrence, and palliative care to alleviate symptoms in advanced cancer cases. Its versatility and efficacy have made it an indispensable tool in the fight against cancer. However, one of the challenges associated with radiation therapy is the potential for radiation-induced toxicities in surrounding healthy tissues.

As healthcare providers continue to harness the potential of radiation therapy to target and destroy cancer cells, the need for effective radiation toxicity treatments has become more pronounced. Patients undergoing radiation therapy may experience side effects such as skin irritation, fatigue, gastrointestinal issues, and damage to nearby organs. This has led to a growing demand for radiation toxicity treatment options that can mitigate these adverse effects, improve patient comfort, and enhance treatment tolerability.

The expanding utilization of radiation therapy across a wide spectrum of cancer types, including lung, breast, prostate, and brain cancer, is driving the growth of the radiation toxicity treatment market. Moreover, technological advancements in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, have improved treatment precision and minimized radiation exposure to healthy tissues. These innovations have not only made radiation therapy more effective but have also reduced the risk of radiation toxicity, further boosting the demand for radiation toxicity treatment.

Technological Advancements in Radiation Therapy

Technological advancements in radiation therapy have been instrumental in boosting the Global Radiation Toxicity Treatment Market. These innovations have not only improved the efficacy of radiation therapy but have also spurred the demand for radiation toxicity treatment solutions.

One of the key drivers behind the market's growth is the development of advanced radiation delivery systems and techniques. Technologies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) have revolutionized the field of radiation oncology. IMRT allows for precise control of radiation beams, enabling oncologists to shape the radiation dose to conform to the contours of the tumor, minimizing exposure to nearby healthy tissues. SBRT, on the other hand, delivers highly focused, high-dose radiation to small tumors or specific areas within tumors, enhancing treatment precision. These techniques not only improve treatment outcomes but also reduce the risk of radiation toxicity, prompting increased utilization of radiation therapy and, consequently, the demand for radiation toxicity treatment.

Proton therapy represents another technological advancement that has reshaped radiation therapy. Proton therapy uses protons rather than traditional X-rays to deliver radiation, offering even greater precision in targeting tumors. This reduces the risk of damaging healthy tissues and lowers the likelihood of radiation toxicity. As proton therapy gains popularity, there is a growing need for specialized radiation toxicity treatment solutions tailored to the unique aspects of this modality.

Furthermore, imaging technologies have played a significant role in advancing radiation therapy. Image-guided radiation therapy (IGRT) and real-time tumor tracking systems allow for continuous monitoring of tumor positions during treatment, ensuring that radiation is delivered with utmost accuracy. This not only enhances treatment efficacy but also minimizes the margin of error, reducing the likelihood of radiation toxicity.

The continuous development of these technologies, along with ongoing research into new approaches like adaptive radiation therapy and particle therapy, keeps the radiation therapy field in a state of rapid evolution. This, in turn, sustains the demand for radiation toxicity treatment solutions that can effectively manage and mitigate any potential side effects associated with these cutting-edge treatments.. options.

Key Market Challenges

Limited Awareness and Education

One of the primary challenges is the lack of awareness among patients undergoing radiation therapy. For many individuals diagnosed with cancer, the focus understandably shifts to the cancer itself and its treatment. Patients may not be fully informed about the potential side effects of radiation therapy, which can include skin irritation, fatigue, gastrointestinal issues, and damage to healthy tissues. Consequently, they may not actively seek information about radiation toxicity treatment options that could mitigate these adverse effects.

This lack of awareness can lead to suboptimal patient experiences, as individuals may not be proactive in discussing radiation toxicity concerns with their healthcare providers. As a result, they may endure unnecessary discomfort and a reduced quality of life during their treatment journey.

Similarly, healthcare professionals may also lack comprehensive knowledge about radiation toxicity treatment options. While radiation oncologists and oncology nurses are experts in their field, they may not be fully aware of the latest advancements in radiation toxicity management. This knowledge gap can lead to missed opportunities for optimizing patient care and improving treatment outcomes. Effective communication between patients and healthcare providers is crucial in addressing radiation toxicity concerns. When healthcare professionals are well-informed about the available radiation toxicity treatments, they can educate and guide patients effectively, ensuring that appropriate measures are taken to manage side effects and enhance patient comfort..

Cost Constraints

One of the primary factors contributing to cost constraints in the radiation toxicity treatment market is the price of treatment options. Advanced pharmaceuticals and medical devices designed to manage radiation-induced side effects can be expensive. These treatment modalities often require ongoing use or specialized administration, which can result in substantial costs for patients and healthcare providers. Additionally, the development and production of radioprotective agents and supportive care products demand substantial research and investment, which can drive up the final cost of these treatments. This cost burden is particularly concerning for patients who may already be grappling with the financial strain of cancer treatment.

Another challenge is the limited insurance coverage for radiation toxicity treatment. Some insurance plans may not fully cover the cost of radiation toxicity management, including radioprotective drugs, supportive care services, and specialized medical devices. This leaves patients responsible for a significant portion of the expenses, which can lead to financial hardship and deter them from seeking necessary treatment.

The cost constraints associated with radiation toxicity treatment also affect healthcare systems and institutions. Hospitals and healthcare providers may face challenges in providing comprehensive radiation toxicity management services due to budgetary constraints. This can result in variations in the quality and availability of radiation toxicity treatment options across different healthcare facilities.

Key Market Trends

Radioprotective Agents and Supportive Care

Radioprotective agents and supportive care have emerged as powerful drivers boosting the Global Radiation Toxicity Treatment Market. These components of radiation toxicity management are gaining increasing attention and significance in the field of cancer care.

Radioprotective agents are pharmaceuticals and treatments developed to shield healthy tissues from the damaging effects of radiation therapy while simultaneously enhancing the tumor's sensitivity to radiation. These agents are designed to minimize radiation-induced toxicities, making radiation therapy safer and more tolerable for patients. The development of radioprotective drugs represents a major breakthrough, as it allows oncologists to optimize radiation treatment protocols without compromising their efficacy. As a result, patients can receive higher doses of radiation to target cancer cells more effectively while experiencing fewer side effects, driving the demand for such agents and boosting the radiation toxicity treatment market.

Supportive care services are another integral aspect of radiation toxicity treatment. These services encompass a range of interventions, including nutritional counseling, physical therapy, psychosocial support, and pain management. Their primary goal is to improve patients' overall well-being and minimize the adverse effects of radiation therapy. By addressing patients' physical, emotional, and psychological needs, supportive care services enhance treatment tolerance and patient satisfaction. The recognition of the importance of holistic patient care has led to an increased demand for these services, further propelling the growth of the radiation toxicity treatment market.

As the radiation oncology field continues to evolve, radioprotective agents and supportive care are becoming essential components of comprehensive cancer treatment plans. Patients and healthcare providers alike are increasingly aware of the benefits of incorporating these measures into radiation therapy protocols.

Personalized Medicine and Targeted Therapies

Personalized medicine in radiation therapy involves a precise understanding of a patient's genetic profile and tumor characteristics. By analyzing genetic markers and other patient-specific factors, oncologists can develop customized radiation treatment plans. This approach allows for the delivery of radiation therapy with maximum precision, ensuring that cancer cells are targeted while minimizing radiation exposure to healthy tissues. As a result, patients experience fewer treatment-related toxicities, which in turn fuels the demand for radiation toxicity treatment options that are compatible with these personalized protocols.

Furthermore, targeted therapies have become instrumental in radiation toxicity treatment. These therapies are designed to selectively target cancer cells or specific biological pathways involved in tumor growth. By integrating targeted therapies with radiation treatment, clinicians can enhance the effectiveness of radiation therapy while minimizing the risk of radiation-induced side effects. The synergy between targeted therapies and radiation therapy is transforming the way cancer is treated, offering a more patient-centered and tailored approach to care.

The rise of personalized medicine and targeted therapies is also driving the development of novel radiation toxicity treatment solutions. Radioprotective agents and supportive care services are being adapted to complement personalized radiation therapy regimens. These treatments not only shield healthy tissues from radiation but also cater to the unique needs of each patient, addressing specific vulnerabilities and susceptibilities.

As the healthcare industry continues to embrace the paradigm shift towards personalized cancer care, the demand for radiation toxicity treatment that aligns with these innovative approaches is set to grow. Patients and healthcare providers are increasingly recognizing the benefits of treatment plans that are designed to maximize therapeutic benefits while minimizing the burden of radiation-induced toxicities. Consequently, the Global Radiation Toxicity Treatment Market is positioned to play a pivotal role in advancing the integration of personalized medicine and targeted therapies into the broader landscape of cancer care, ultimately enhancing patient outcomes and the overall quality of radiation therapy.

Segmental Insights

Product Insights

Based on the Product, the Colony Stimulating Factors emerged as the dominant segment in the global market for Global Radiation Toxicity Treatment Market in 2022. The primary reason for this is the critical role Colony Stimulating Factors (CSFs) play in mitigating the effects of radiation-induced toxicity, particularly in the context of cancer treatment and radiation therapy. Radiation therapy is a common treatment modality for various cancers, including breast, lung, and prostate cancer. Since CSFs are a standard part of supportive care for cancer patients undergoing radiation therapy, they are in high demand in oncology settings.

Indication Insights

Based on the Indication, the Chronic Radiation Syndrome emerged as the dominant player in the global market for Global Radiation Toxicity Treatment Market in 2022. Chronic radiation syndrome typically arises from prolonged or repeated exposure to ionizing radiation over an extended period. This is often seen in occupational settings, such as nuclear power plants, radiological laboratories, and certain industrial environments. Long-term exposure scenarios are more common than acute radiation incidents, resulting in a higher prevalence of chronic radiation syndrome cases.

Regional Insights

North America emerged as the dominant player in the global Radiation Toxicity Treatment Market in 2022, holding the largest market share. North America boasts a highly advanced and sophisticated healthcare infrastructure, with state-of-the-art medical facilities, research institutions, and cutting-edge technology. This infrastructure enables the region to provide top-quality radiation therapy and radiation toxicity treatment services, attracting patients not only from within the region but also from around the world. North America has a relatively high incidence of cancer cases. This increased prevalence of cancer drives the demand for radiation therapy as a primary treatment modality. Consequently, there is a greater need for effective radiation toxicity treatment in the region to manage the side effects associated with radiation therapy.

Key Market Players

• Amgen Inc.

• Jubilant Pharma Limited

• Tanner Pharma Group

• Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG

• Recipharm AB

• Mission Pharmacal Company

• Partner Therapeutics, Inc.

• Novartis AG

• Mylan NV

• Coherus Biosciences Inc

Report Scope:

In this report, the Global Radiation Toxicity Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Radiation Toxicity Treatment Market, By Product:

• Colony Stimulating Factors
• Potassium Iodide
• Prussian Blue Diethylenetriamine Pentaacetic Acid
• Others

Global Radiation Toxicity Treatment Market, By Indication:

• Acute Radiation Syndrome
• Chronic Radiation Syndrome

Global Radiation Toxicity Treatment Market, By End-user :

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Global Radiation Toxicity Treatment Market, By Radiation Type:

• Ionizing Radiation
• Non-ionizing Radiation

Global Radiation Toxicity Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Radiation Toxicity Treatment Market.

Available Customizations:

• Global Radiation Toxicity Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Radiation Toxicity Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product (Colony Stimulating Factors, Potassium Iodide, Prussian Blue Diethylenetriamine Pentaacetic Acid, Others)
  • 4.2.2. By Indication (Acute Radiation Syndrome, Chronic Radiation Syndrome)
  • 4.2.3. By Radiation Type (Ionizing Radiation, Non-ionizing Radiation)
  • 4.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.5. By Region
  • 4.2.6. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Product
  • 4.3.2. By Indication
  • 4.3.3. By Radiation Type
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Asia Pacific Radiation Toxicity Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product
  • 5.2.2. By Indication
  • 5.2.3. By Radiation Type
  • 5.2.4. By End-user
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Radiation Toxicity Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product
      • 5.3.1.2.2. By Indication
      • 5.3.1.2.3. By Radiation Type
      • 5.3.1.2.4. By End-user
  • 5.3.2. India Radiation Toxicity Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product
      • 5.3.2.2.2. By Indication
      • 5.3.2.2.3. By Radiation Type
      • 5.3.2.2.4. By End-user
  • 5.3.3. Australia Radiation Toxicity Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product
      • 5.3.3.2.2. By Indication
      • 5.3.3.2.3. By Radiation Type
      • 5.3.3.2.4. By End-user
  • 5.3.4. Japan Radiation Toxicity Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product
      • 5.3.4.2.2. By Indication
      • 5.3.4.2.3. By Radiation Type
      • 5.3.4.2.4. By End-user
  • 5.3.5. South Korea Radiation Toxicity Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product
      • 5.3.5.2.2. By Indication
      • 5.3.5.2.3. By Radiation Type
      • 5.3.5.2.4. By End-user

6. Europe Radiation Toxicity Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By Radiation Type
  • 6.2.4. By End-user
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Radiation Toxicity Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Radiation Type
      • 6.3.1.2.4. By End-user
  • 6.3.2. Germany Radiation Toxicity Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Radiation Type
      • 6.3.2.2.4. By End-user
  • 6.3.3. Spain Radiation Toxicity Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Radiation Type
      • 6.3.3.2.4. By End-user
  • 6.3.4. Italy Radiation Toxicity Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Indication
      • 6.3.4.2.3. By Radiation Type
      • 6.3.4.2.4. By End-user
  • 6.3.5. United Kingdom Radiation Toxicity Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Indication
      • 6.3.5.2.3. By Radiation Type
      • 6.3.5.2.4. By End-user

7. North America Radiation Toxicity Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By End-user
  • 7.2.4. By Radiation Type
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Radiation Toxicity Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Radiation Type
      • 7.3.1.2.4. By End-user
  • 7.3.2. Mexico Radiation Toxicity Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Radiation Type
      • 7.3.2.2.4. By End-user
  • 7.3.3. Canada Radiation Toxicity Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Radiation Type
      • 7.3.3.2.4. By End-user

8. South America Radiation Toxicity Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Radiation Toxicity Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Radiation Type
      • 8.3.1.2.4. By End-user
  • 8.3.2. Argentina Radiation Toxicity Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Radiation Type
      • 8.3.2.2.4. By End-user
  • 8.3.3. Colombia Radiation Toxicity Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Radiation Type
      • 8.3.3.2.4. By End-user

9. Middle East and Africa Radiation Toxicity Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Drug Type
  • 9.2.3. By Radiation Type
  • 9.2.4. By End-user
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Radiation Toxicity Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Radiation Type
      • 9.3.1.2.4. By End-user
  • 9.3.2. Saudi Arabia Radiation Toxicity Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Radiation Type
      • 9.3.2.2.4. By End-user
  • 9.3.3. UAE Radiation Toxicity Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Radiation Type
      • 9.3.3.2.4. By End-user
  • 9.3.4. Egypt Radiation Toxicity Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Indication
      • 9.3.4.2.3. By Radiation Type
      • 9.3.4.2.4. By End-user

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Radiation Toxicity Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Amgen Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Jubilant Pharma Limited
• 14.3. Tanner Pharma Group
• 14.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
• 14.5. Recipharm AB
• 14.6. Mission Pharmacal Company
• 14.7. Partner Therapeutics, Inc.
• 14.8. Novartis AG
• 14.9. Mylan NV
• 14.10. Coherus Biosciences Inc.

15. Strategic Recommendations

16. About Us & Disclaimer